Why did RXRX stock jump? — 2026-11-18

Research session: 2026-11-18. Published: 2026-11-18T21:34:01.337379+00:00.

Final report

RXRX — Recursion Pharmaceuticals, Inc. - Class A Common Stock

Session close: $2.83. Regular-session share volume: 37,421,816. Change from previous close: +3.86%.

Key developments

Morgan Stanley maintained a Hold rating on Recursion while lowering its price target, reflecting a tempered assessment of the company's market position and outlook. Separate commentary noted the stock has been weak over the past year and questioned the original thesis around clinical risk, cash needs and partnership dependence.

Company news Morgan Stanley Maintains Hold Rating on Recursion Pharmaceuticals, Lowers Price Target · Company news What Recursion Pharmaceuticals Investors Missed Before The Fall

News sources

Company news Morgan Stanley Maintains Hold Rating on Recursion Pharmaceuticals, Lowers Price Target · Company news What Recursion Pharmaceuticals Investors Missed Before The Fall

Full report for 2026-11-18